ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patientsConferences, MyelomaDecember 5, 2020
ASH 2020 | Visit our poster on myeloma patient information needs and preferences at ASH 2020!Conferences, MPE, MyelomaDecember 5, 2020
